EcoDrugPlus

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSPNYG00000012856
Gene Symbol: NR3C2
3 Cross references
209 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSPNYG00000010746
Gene Symbol: NOD2
3 Cross references
166 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSPNYG00000001599
Gene Symbol: OPRK1
2 Cross references
197 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSPNYG00000015290
Gene Symbol: OPRL1
3 Cross references
189 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSPNYG00000014581
Gene Symbol: OXTR
3 Cross references
183 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSPNYG00000006726
Gene Symbol: OXTR
3 Cross references
191 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSPNYG00000016031
Gene Symbol: PTH1R
3 Cross references
196 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSPNYG00000006576
Gene Symbol: PPARA
3 Cross references
383 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSPNYG00000018859
Gene Symbol: PPARG
4 Cross references
386 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha-Like

Ensembl ID : ENSPNYG00000007356
Gene Symbol: LOC102205686
3 Cross references
396 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Delta B

Ensembl ID : ENSPNYG00000022354
Gene Symbol: PPARDB
1 Cross references
392 Possible Orthologues:

Phosphatidylinositol 3-Kinase Regulatory Subunit Gamma-Like

Ensembl ID : ENSPNYG00000020525
Gene Symbol: LOC102198353
3 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).